🇺🇸 FDA

Intelligence Platform

Patents

Browse 29,054 pharma-relevant patents (US and EP, A61K/A61P) linked to tracked companies. Patent cliff and LOE intelligence for BD teams.

29,054 patents indexed
patent

US 12279630

Treatment and prevention of seed allergies

TEL HASHOMER MEDICAL RESEARCH INFRASTRUCTURE AND SERVICES LTD. · Granted Tue Apr 22 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 17 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12280055

Combination therapies

Mirati Therapeutics, Inc. · Granted Tue Apr 22 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 17 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12280063

Anti-retroviral therapies and reverse transcriptase inhibitors for treatment of Alzheimer'

SANFORD BURNHAM PREBYS MEDICAL DISCOVERY INSTITUTE · Granted Tue Apr 22 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 17 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12280088

Dry powder formulation of caveolin-1 peptides and methods of use thereof

The Board of Regents of the University of Texas System · Granted Tue Apr 22 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 17 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12280037

Method and pharmaceutical composition for treating or preventing trichomoniasis and uses t

EVOFEM BIOSCIENCES, INC. · Granted Tue Apr 22 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 17 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12280089

Dry powder formulation of caveolin-1 peptides and methods of use thereof

The Board of Regents of the University of Texas System · Granted Tue Apr 22 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 17 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12280108

Vaccines having an antigen and interleukin-21 as an adjuvant

Inovio Pharmaceuticals, Inc. · Granted Tue Apr 22 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 17 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12280029

Methods of treatment of inflammation related conditions using pluripotent anti-inflammator

INSTITUT PASTEUR DE MONTEVIDEO · Granted Tue Apr 22 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 17 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12280113

Ras inhibitors

Revolution Medicines, Inc. · Granted Tue Apr 22 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 17 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12280124

Antibody-drug conjugates comprising GLP1 peptidomimetics and uses thereof

REGENERON PHARMACEUTICALS, INC. · Granted Tue Apr 22 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 17 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12280120

Tumor-specific cleavable linkers

Xilio Development, Inc. · Granted Tue Apr 22 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 17 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12281329

Compositions and methods for immune cell modulation in adoptive immunotherapies

Fate Therapeutics, Inc. · Granted Tue Apr 22 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 17 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12281310

Use of trinucleotide repeat RNAs to treat cancer

Northwestern University · Granted Tue Apr 22 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 17 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12281321

Frataxin expression constructs having engineered promoters and methods of use thereof

VOYAGER THERAPEUTICS, INC. · Granted Tue Apr 22 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 17 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12281305

Compounds and methods for reducing prion expression

Ionis Pharmaceuticals, Inc. · Granted Tue Apr 22 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 17 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12281122

PI3K inhibitors

Cogent Biosciences, Inc. · Granted Tue Apr 22 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 17 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12281140

Bile acid derivatives as FXR/TGR5 agonists and methods of use thereof

Enanta Pharmaceuticals, Inc. · Granted Tue Apr 22 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 17 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12281327

Lymphohematopoietic engineering using CAS9 base editors

Regents of the University of Minnesota · Granted Tue Apr 22 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 17 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12281164

Genetically engineered dual-targeting chimeric antigen receptor and use thereof

WEST CHINA HOSPITAL, SICHUAN UNIVERSITY · Granted Tue Apr 22 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 17 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12281113

Crystalline forms of a KRas G12C inhibitor

Mirati Therapeutics, Inc. · Granted Tue Apr 22 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 17 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12281173

Methods for treating patients with hyperlipidemia by administering a PCSK9 inhibitor in co

REGENERON PHARMACEUTICALS, INC. · Granted Tue Apr 22 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 17 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12281083

2-substituted amino-naphth (1,2-d) imidazol-5-one compounds of pharmaceutically acceptable

PTC THERAPEUTICS, INC. · Granted Tue Apr 22 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 17 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12281105

Contraceptive compounds and methods

Regents of the University of Minnesota · Granted Tue Apr 22 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 17 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12281060

Remodilins for airway remodeling and organ fibrosis

The United States of America, as represented by the Secretary, Department of Health and Human Services · Granted Tue Apr 22 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 17 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

granted